Business
Board Appointments
Board Appointments.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 2845V Oxford BioDynamics PLC 05 April 2019 \n\n5 April 2019\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics strengthens commercial focus with two Board appointments\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces, further to the announcement on 11 January 2019, the appointments of David Holbrook and Peter Pack to the Board of Directors as Independent Non-Executive Directors. In addition, David Williams has today stepped down from the Board as Non-Executive Chairman.\n \nSteve Diggle, Non-Executive Director, will become Non-Executive Chairman of OBD's Board on an interim basis, replacing David Williams. Alison Kibble will step down from the Board and as Chair of the Audit Committee after the announcement of the Group's interim results. David Holbrook and Peter Pack will each join the Company's Remuneration Committee, which will be chaired by Peter Pack, and Audit Committee.\n \nDr David Holbrook is a proven leader in business development and healthcare investing, with 30 years' experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.\n \nDr Peter Pack, currently Chief Executive Officer of Crescendo Biologics, brings over 25 years' experience of successfully establishing and growing international life sciences companies. At Crescendo, he has led the company through a $70 million fund raising and successfully completed a major licensing deal with Takeda for ...